Daily Management Review

An Experimental COVID-19 Vaccine Trigger Immune Response In Both Young And Old


British Health Secretary does not rule out the possibility of the vaccine reaching some people in 2020 itself.

If Reuters reports are to be believed, one experimental vaccine for COVID-19 has triggered immune response in young as well as old adults, which has kindled hopes for ending the “gloom and economic destruction” caused by the outbreak of COVID-19 pandemic.
The said vaccine has been developed by the University of Oxford. Moreover, it has also triggered “lower adverse responses” in the elderly population, reported AstraZeneca Plc, British drug manufacturer helping in the vaccine manufacturing. According to a spokesperson of AstraZeneca:
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher”.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222”.
The vaccine thus developed in collaboration of Oxford and AstraZeneca is “expected to be one of the first” among the big pharmaceutical companies to receive “regulatory approval”. While other candidates for this run include “Pfizer and BioNTech”.
Since, the virus weakens the immune system putting the older people at most risk, the success of the vaccine would bring in some “measure of normality” in the world post tumultuous pandemic affects. The “British Health Secretary”, Matt Hancock informed that as yet no vaccine is ready but preparations are on for possible roll out in the “first half of 2021”.
Commenting on the possibility of some people receiving the vaccine in 2020 itself, Hancock said:
“I don’t rule that out but that is not my central expectation.”
“The programme is progressing well, (but) we’re not there yet”.
Referring to an earlier report of the Financial Times, Reuters added:
“Immunogenicity blood tests carried out on a subset of older participants echo data released in July which showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55”.
The details of the same are yet to be revealed through a clinical journal, although no specific journal names were indicated.